undamentalytics Newsletter

Tango Therapeutics, Inc. valuation and forecast

Explore the models for Tango Therapeutics, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: free cash flow after stock pay is not positive.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Your valuation workspace

What is TNGX worth to you?

Start with the company's financial data. Make the assumptions your own.

2 models available

01 / Assumptions

Follow the forecast

The cash flows behind your value

USD per share
View annual figures
Forecast yearCash flow / share

Negative cash flows are shown in terracotta. Before the terminal value and equity bridge. Residual-income models show excess earnings; dividend models show dividends.

See the range of possibilities

Compare and combine your models

Your weighted value—

Weights start with the platform's included models. Change them to build your own combination. Select a model name to edit its assumptions.

ModelYour value / shareWeight

The platform's price and consistency filters are not reapplied to your scenarios.

Other model types 20 unavailable for TNGX

Price-to-earnings vs peers

This model is withheld pending its input or assumption review.

Residual income

This model is withheld pending its input or assumption review.

Justified price-to-book

This model is withheld pending its input or assumption review.

Cash-flow DCF

This model does not apply to this company with the available financial data.

Growth DCF

This model does not apply to this company with the available financial data.

P/B vs return on equity

This model does not apply to this company with the available financial data.

Peer price-to-book

This model does not apply to this company with the available financial data.

Peer price-to-FFO

This model does not apply to this company with the available financial data.

Peer price-to-sales

This model does not apply to this company with the available financial data.

Forward peer P/E

This model does not apply to this company with the available financial data.

P/E comparison

This model does not apply to this company with the available financial data.

P/S comparison

This model does not apply to this company with the available financial data.

PEG comparison

This model does not apply to this company with the available financial data.

Two-stage dividend discount

This model does not apply to this company with the available financial data.

Growing-dividend model

This model does not apply to this company with the available financial data.

REIT funds from operations

This model does not apply to this company with the available financial data.

Utility earnings

This model does not apply to this company with the available financial data.

Book value / net assets

This model does not apply to this company with the available financial data.

Reported crypto treasury NAV

This model does not apply to this company with the available financial data.

Proved-reserve NAV

This model does not apply to this company with the available financial data.

Model values are estimates under the assumptions shown. They are not share-price forecasts or investment advice.

Valuation models compared

Revenue-to-maturity modelcash margin -342.9% → 17.1%, 10% discount
~$0.1
Forward price-to-sales vs peersleft out of the combined value: out of range vs price (0.00x)
~$0.1~$0.1–$0.2

Different models answer different questions: the cash-flow models ask what the business generates for owners; the peer multiples ask what similar companies in our coverage trade on. Where they disagree, the gap is the story. Projections are estimates based on current data, updated daily. Not investment advice. How each model works.

Analyst recommendations

13 analysts, Oct 2026
Buy1292%
Hold18%
Sell00%

Monthly trend

  1. Oct 2026111113
  2. Sep 2026110112
  3. Aug 2026111113
  4. Jul 2026111113

Counts of recommendations published by analysts covering Tango Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

TNGX valuation questions

How does Fundamentalytics value Tango Therapeutics, Inc.?
We use the models that fit Tango Therapeutics, Inc.'s business and available financial data. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved October 29, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Tango Therapeutics, Inc.

Compare with peers